Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tissue Repair Gel in Venous Leg Ulcers (US)

NCT06707090

Venous Leg Ulcer Venous Ulcer Venous Stasis Ulcer +5 more

RECRUITING PHASE3

Tissue Repair Gel in Venous Leg Ulcers in AU/US

NCT06707103

Venous Leg Ulcer Venous Ulcer Venous Stasis Ulcer +5 more

RECRUITING PHASE3

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

NCT00288392

Foot Ulcer

COMPLETED PHASE2

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

NCT01656889

Venous Leg Ulcers

COMPLETED PHASE3

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

NCT03077165

Venous Leg Ulcer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the effectiveness of TR 987 gel. It is a two-arm, design: One group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks. The other group will receive twice-weekly applications of placebo gel base plus SoC for the same period of time. After 4 weeks, both groups will receive once weekly applications of their assigned treatment for the remaining 8 weeks of the trial. The Standard of Care therapy in this study is multi-layer compression therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TR987

This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.

Group Type ACTIVE_COMPARATOR

0.1% TR 987

Intervention Type DRUG

TR 987 0.1%

Placebo

This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.

Group Type PLACEBO_COMPARATOR

Placebo gel

Intervention Type DRUG

Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.1% TR 987

TR 987 0.1%

Intervention Type DRUG

Placebo gel

Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Beta glucan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is at least 18 years old
2. Female subjects are not pregnant or breastfeeding.
3. Study ulcer has been present for at least one month and has undergone more than 2 weeks, but less than 12 months of continuous high-strength compression with less than 40% healing.
4. Study ulcer is a minimum of 2.0 cm2 and a maximum of 20.0 cm2, extending through the full thickness of the skin, but not down to muscle, tendon, or bone at the randomization visit.
5. Study ulcer has a clean, granulating base with minimal adherent slough at the randomization visit.
6. If more than one ulcer is present on the same leg, they must be more than 2 cm apart and only the larger ulcer will be included in the study.
7. Adequate arterial flow, as measured by an Ankle Brachial Pressure Index (ABI) of greater than 0.75. (Calculations will be made using measurements from both posterior tibial and dorsalis pedis arteries, as well as both arms) and/or Skin Perfusion Pressure (SPP) \>30.
8. Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
9. Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
10. Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria

1. Study ulcer deemed by the Investigator to be caused by a medical condition other than venous insufficiency.
2. Study ulcer exhibits clinical signs and symptoms of infection.
3. Study ulcer requires enzymatic debridement during the study.
4. Study ulcer has undergone 12 or more months of continuous high-strength compression therapy over its duration.
5. Study ulcer is less than 2.0 cm2 or greater than 20.0 cm2.
6. Study ulcer extends more than 50% below the malleolus.
7. Study ulcer is treated with a topical antibiotic during the screening phase.
8. Study ulcer has been treated with tissue engineered material (e.g., Apligraf® or Dermagraft®) or other scaffold materials (e.g., Oasis or Matristem) within 30 days prior to the TV1 Randomization visit.
9. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the course of the trial.
10. History of radiation at the study ulcer site.
11. Study ulcer decreases in area by 30% or more during the 14 days screening period.
12. Subjects who are unable to understand the aims and objectives of the trial or has a known history of poor adherence with medical treatment.
13. Presence of any condition(s) that seriously compromises the subject's ability to complete this study.
14. All females of childbearing potential who are not using a highly effective method of birth control (failure rate less than 1% per year), such implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No